JAK 抑制剂在 COVID-19 中的应用：警惕固有血栓形成风险增加的必要性。
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.
机构信息
Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.
Dept of Rheumatology, University College London (UCL) Centre for Adolescent Rheumatology, London, UK.
出版信息
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01919-2020. Print 2020 Sep.
Abstract
摘要
相似文献
1
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.JAK 抑制剂在 COVID-19 中的应用：警惕固有血栓形成风险增加的必要性。
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01919-2020. Print 2020 Sep.
2
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.新型冠状病毒肺炎如何影响在风湿病学和皮肤病学中接受抗细胞因子和JAK抑制剂治疗的患者。
Immunotherapy. 2020 Oct;12(15):1115-1119. doi: 10.2217/imt-2020-0153. Epub 2020 Jul 9.
3
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?巴瑞替尼、JAK抑制剂与肝损伤：新冠疫情中值得关注的问题？
Expert Opin Drug Saf. 2020 Oct;19(10):1367-1369. doi: 10.1080/14740338.2020.1812191. Epub 2020 Aug 25.
4
[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].[在重症新型冠状病毒肺炎患者中使用JAK 1/2抑制剂的理论依据]
Ugeskr Laeger. 2020 Jun 15;182(25).
5
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.回复：暴风雨前的平静：了解Janus激酶抑制剂在COVID-19中的作用。
J Am Acad Dermatol. 2020 Jul;83(1):e67-e68. doi: 10.1016/j.jaad.2020.04.097. Epub 2020 Apr 25.
6
COVID-19 and pulmonary embolism: an unwanted alliance.新型冠状病毒肺炎与肺栓塞：一种不良组合。
Eur Heart J. 2020 Jul 1;41(32):3069-3071. doi: 10.1093/eurheartj/ehaa553.
7
COVID-19 and Pulmonary Embolism: Diagnostic Imaging Trends.新型冠状病毒肺炎与肺栓塞：诊断成像趋势
J Nucl Med. 2020 Aug;61(8):1102. doi: 10.2967/jnumed.120.248518. Epub 2020 May 22.
8
Reply: COVID-19 and Pulmonary Embolism: Diagnostic Imaging Trends.回复：2019冠状病毒病与肺栓塞：诊断成像趋势
J Nucl Med. 2020 Aug;61(8):1102-1103. doi: 10.2967/jnumed.120.250530. Epub 2020 Jun 23.
9
Are subpleural consolidations indicators for segmental pulmonary embolism in COVID-19?胸膜下实变是新型冠状病毒肺炎（COVID-19）节段性肺栓塞的指标吗？
Intensive Care Med. 2020 Jun;46(6):1109-1110. doi: 10.1007/s00134-020-06044-z. Epub 2020 Apr 23.
10
Acute pulmonary embolism in COVID-19 disease.新型冠状病毒肺炎相关急性肺栓塞
Int J Cardiol. 2020 Nov 15;319:151. doi: 10.1016/j.ijcard.2020.06.063. Epub 2020 Jul 3.
引用本文的文献
1
d-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection.一名长期使用托法替布治疗且近期感染新型冠状病毒肺炎的类风湿关节炎患者的D-二聚体变化趋势
Rev Colomb Reumatol. 2022 Jun;29:S84-S87. doi: 10.1016/j.rcreu.2021.06.003. Epub 2021 Jul 5.
2
Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.新冠疫情掩盖下的自身免疫性肝炎：潜在关联性质分析
Front Immunol. 2025 Jan 31;16:1510770. doi: 10.3389/fimmu.2025.1510770. eCollection 2025.
3
The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.2019冠状病毒病中炎症与血栓形成的相互作用：机制、治疗策略及挑战
Thromb Update. 2022 Aug;8:100117. doi: 10.1016/j.tru.2022.100117. Epub 2022 Jul 9.
4
Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.与 COVID-19 感染及相关细胞因子风暴相关的表观遗传学观点：最新综述。
Infection. 2023 Dec;51(6):1603-1618. doi: 10.1007/s15010-023-02017-8. Epub 2023 Mar 12.
5
An overview on the treatments and prevention against COVID-19.关于 COVID-19 的治疗和预防概述。
Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9.
6
Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis.用于2019冠状病毒病的Janus激酶抑制剂：一项成对和贝叶斯网络荟萃分析。
Front Med (Lausanne). 2022 Nov 23;9:973688. doi: 10.3389/fmed.2022.973688. eCollection 2022.
7
A multi-reference poly-conformational method for design, optimization, and repositioning of pharmaceutical compounds illustrated for selected SARS-CoV-2 ligands.多参照多构象方法用于药物化合物的设计、优化和再定位，文中选用了一些 SARS-CoV-2 配体作为案例进行说明。
PeerJ. 2022 Nov 24;10:e14252. doi: 10.7717/peerj.14252. eCollection 2022.
8
COVID-19 and the antiphospholipid syndrome.新型冠状病毒肺炎与抗磷脂综合征。
Autoimmun Rev. 2022 Dec;21(12):103206. doi: 10.1016/j.autrev.2022.103206. Epub 2022 Oct 3.
9
IFN- Is Protective in Cytokine Release Syndrome-associated Extrapulmonary Acute Lung Injury.IFN- 在细胞因子释放综合征相关的肺外急性肺损伤中具有保护作用。
Am J Respir Cell Mol Biol. 2023 Jan;68(1):75-89. doi: 10.1165/rcmb.2022-0117OC.
10
Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.血小板与酪氨酸激酶抑制剂：临床特征、作用机制及对生理功能的影响。
Am J Physiol Cell Physiol. 2022 Oct 1;323(4):C1231-C1250. doi: 10.1152/ajpcell.00040.2022. Epub 2022 Aug 8.
本文引用的文献
1
Coagulation abnormalities and thrombosis in patients with COVID-19.新型冠状病毒肺炎患者的凝血异常与血栓形成
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
2
Pulmonary embolism in patients with COVID-19 pneumonia.COVID-19 肺炎患者中的肺栓塞。
Eur Respir J. 2020 Jul 30;56(1). doi: 10.1183/13993003.01365-2020. Print 2020 Jul.
3
Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?新型冠状病毒 2 型患者的静脉血栓栓塞症：仅仅是在通气 ICU 患者中存在问题，还是有更多问题？
Eur Respir J. 2020 Jul 30;56(1). doi: 10.1183/13993003.01201-2020. Print 2020 Jul.
4
COVID-19 and its implications for thrombosis and anticoagulation.新型冠状病毒肺炎及其对血栓形成和抗凝的影响。
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
COVID-19: combining antiviral and anti-inflammatory treatments.2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
7
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
8
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.巴瑞替尼用于中度至重度特应性皮炎且对局部皮质类固醇反应不佳的患者：两项随机单药治疗III期试验的结果
Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5.
9
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.Janus 激酶抑制剂对类风湿关节炎患者心血管事件风险的影响：随机对照试验的系统评价和荟萃分析。
Ann Rheum Dis. 2019 Aug;78(8):1048-1054. doi: 10.1136/annrheumdis-2018-214846. Epub 2019 May 14.
10
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.巴瑞替尼治疗类风湿关节炎的心血管安全性。
Arthritis Rheumatol. 2019 Jul;71(7):1042-1055. doi: 10.1002/art.40841. Epub 2019 May 25.
Zotero 插件